162 related articles for article (PubMed ID: 23566753)
1. Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose.
Pongtanakul B; Viprakasit V
Blood Cells Mol Dis; 2013 Aug; 51(2):96-7. PubMed ID: 23566753
[No Abstract] [Full Text] [Related]
2. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
Chang HH; Lu MY; Liao YM; Lin PC; Yang YL; Lin DT; Chiou SS; Jou ST; Lin KH; Chang TT
Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825
[TBL] [Abstract][Full Text] [Related]
3. Deferasirox treatment may be associated with reversible renal Fanconi syndrome.
Even-Or E; Becker-Cohen R; Miskin H
Am J Hematol; 2010 Feb; 85(2):132-4. PubMed ID: 20052747
[No Abstract] [Full Text] [Related]
4. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Balocco M; Carrara P; Pinto V; Forni GL
Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
[No Abstract] [Full Text] [Related]
5. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.
Taher AT; Temraz S; Cappellini MD
Expert Rev Hematol; 2013 Oct; 6(5):495-509. PubMed ID: 24083402
[TBL] [Abstract][Full Text] [Related]
6. Deferasirox and children: From clinical trials to the real world.
Origa R; Zappu A; Foschini ML; Leoni G; Morittu M; Moi P; Corpino M; Dessì C
Am J Hematol; 2016 Jun; 91(6):E304-5. PubMed ID: 26950047
[No Abstract] [Full Text] [Related]
7. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
[TBL] [Abstract][Full Text] [Related]
8. Transitioning Patients With Iron Overload From Exjade to Jadenu.
Tinsley SM; Hoehner-Cooper CM
J Infus Nurs; 2018; 41(3):171-175. PubMed ID: 29659464
[TBL] [Abstract][Full Text] [Related]
9. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
10. Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia.
Koh KN; Park M; Kim BE; Im HJ; Seo JJ
J Pediatr Hematol Oncol; 2010 Nov; 32(8):611-4. PubMed ID: 20881872
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
Galanello R
Ann N Y Acad Sci; 2005; 1054():183-5. PubMed ID: 16339664
[TBL] [Abstract][Full Text] [Related]
12. Iranian experience of deferasirox (Exjade(®)) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels?
Karimi M; Azarkeivan A; Zareifar S; Cohan N; Bordbar MR; Haghpanah S
Hematology; 2012 Nov; 17(6):367-71. PubMed ID: 23168076
[TBL] [Abstract][Full Text] [Related]
13. The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan.
Chang HH; Lu MY; Peng SS; Yang YL; Lin DT; Jou ST; Lin KH
Ann Hematol; 2015 Dec; 94(12):1945-52. PubMed ID: 26404899
[TBL] [Abstract][Full Text] [Related]
14. Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.
Shirley M; Plosker GL
Drugs; 2014 Jun; 74(9):1017-27. PubMed ID: 24919862
[TBL] [Abstract][Full Text] [Related]
15. The administration of deferasirox in an iron-overloaded dialysis patient.
Tsai CW; Yang FJ; Huang CC; Kuo CC; Chen YM
Hemodial Int; 2013 Jan; 17(1):131-3. PubMed ID: 22549006
[No Abstract] [Full Text] [Related]
16. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.
Taher AT; Cappellini MD; Aydinok Y; Porter JB; Karakas Z; Viprakasit V; Siritanaratkul N; Kattamis A; Wang C; Zhu Z; Joaquin V; Uwamahoro MJ; Lai YR
Blood Cells Mol Dis; 2016 Mar; 57():23-9. PubMed ID: 26852651
[TBL] [Abstract][Full Text] [Related]
17. [Pathogenesis of transfusional iron overload and iron chelation therapy].
Ozawa K
Rinsho Ketsueki; 2009 Jul; 50(7):527-31. PubMed ID: 19638719
[No Abstract] [Full Text] [Related]
18. The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload.
Sivgin S; Baldane S; Akyol G; Keklik M; Kaynar L; Kurnaz F; Pala C; Zararsiz G; Cetin M; Eser B; Unal A
Transfus Apher Sci; 2013 Oct; 49(2):295-301. PubMed ID: 23916904
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox--an oral agent for chronic iron overload.
Vanorden HE; Hagemann TM
Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
[TBL] [Abstract][Full Text] [Related]
20. Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.
Wei HY; Yang CP; Cheng CH; Lo FS
Transfusion; 2011 May; 51(5):949-54. PubMed ID: 21077910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
